scispace - formally typeset
A

Anette Duensing

Researcher at University of Pittsburgh

Publications -  71
Citations -  5945

Anette Duensing is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Imatinib mesylate & Centrosome. The author has an hindex of 30, co-authored 69 publications receiving 5519 citations. Previous affiliations of Anette Duensing include Brigham and Women's Hospital.

Papers
More filters
Journal ArticleDOI

PDGFRA Activating Mutations in Gastrointestinal Stromal Tumors

TL;DR: Tumors expressing KIT or PDGFRA oncoproteins were indistinguishable with respect to activation of downstream signaling intermediates and cytogenetic changes associated with tumor progression, suggesting KIT and PDGFra mutations appear to be alternative and mutually exclusive oncogenic mechanisms in GISTs.
Journal ArticleDOI

The human papillomavirus type 16 E6 and E7 oncoproteins cooperate to induce mitotic defects and genomic instability by uncoupling centrosome duplication from the cell division cycle.

TL;DR: It is shown that aberrant mitotic spindle pole formation caused by abnormal centrosome numbers represents an important mechanism in accounting for numeric chromosomal alterations in HPV-associated carcinogenesis.
Journal ArticleDOI

ERCC1-XPF Endonuclease Facilitates DNA Double-Strand Break Repair

TL;DR: Data support the conclusion that, as in yeast, ERCC1-XPF facilitates DSB repair via an end-joining mechanism that is Ku86 independent, and in vitro repair of DSBs with 3′ overhangs led to large deletions in the absence of ERCC 1- XPF.
Journal ArticleDOI

KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway

TL;DR: It is concluded that GIST secondary KIT mutations can be associated with KIT hyperactivation and imatinib resistance, and targeting critical downstream signaling proteins, such as PI3-K, is a promising therapeutic strategy inImatinib-resistant GISTs.